Clinical Trial Update: Faslodex 500mg Multiple Dose Tolerability Study in BC Patients [Phase 1]

View source ↗

Summary

Phase 1 tolerability study of Faslodex (fulvestrant) 500 mg in patients with breast cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Breast Cancer | Phase 1 | Status: COMPLETED